Trial Profile
Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 24 Oct 2018 Interim results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 22 Oct 2018 Status changed from active, no longer recruiting to completed.
- 29 Jul 2018 Planned End Date changed from 30 Jun 2018 to 31 Aug 2019.